Posted 30th September 2019 by Joshua Sewell
Global Engage spoke to Scott Kahn ahead of the 3rdGlobal Pharma R&D Informatics and AI Congress. Scott is the CIO of Luna PBC, the entity that manages LunaDNA: a community-owned data-sharing resource. Their conversation was recorded as a podcast, which can be found here.
This is the second half of that conversation, where Scott discusses the challenges of distributive ledger technologies such as Blockchain, and their intersection with AI for Pharma R&D.
Posted 23rd September 2019 by Joshua Sewell
Ahead of the 3rd Global Pharma R&D Informatics and AI Congress, Global Engage spoke to Scott Kahn, CIO of LunaPBC. LunaPBC is the company that manages LunaDNA: a community-owned data-sharing resource. Their conversation was recorded as a podcast, which can be found here.
In the first half of the conversation, Scott discusses the benefits of distributive ledger technologies such as Blockchain for Pharma R&D.
Posted 9th September 2019 by Joshua Sewell
As Chief Data Officer for the OSTHUS Group, Eric Little co-founded LeapAnalysis, a new approach to AI, data integration and analytics.
LeapAnalysis is the first fully federated and virtualised search and analytics engine that runs on semantic metadata. It allows users to combine semantic models (ontologies) with machine learning algorithms to provide customers with unparalleled flexibility in utilizing their data.
Posted 19th August 2019 by Jane Williams
e-Therapeutics, an Oxford-based company, is using its network-driven drug discovery (NDD) technology to embrace the inherent complexity of biology, providing a novel and productive method for the discovery of new medicines.
Jonny Wray is the head of Discovery Informatics at e-Therapeutics. Trained as a computational neuroscientist, he is responsible for building the NDD technology. We spoke to him ahead of his presentation at the Global Pharma R&D Informatics & AI Congress.
Posted 2nd August 2019 by Jane Williams
With a background in pharmacology, toxicology, molecular cell biology and genetics, Rangaprasad Sarangarajan joined BERG Health in 2010 as head of R&D.
In the initial years of the company, he aided in the conception, design, and implementation of the paradigm of looking at human biology, use of technology to generate molecular signatures, and the use of artificial intelligence-based analytics for understanding the complexity of biology, identifying of targets, and developing of drugs, and its utility in clinical development.
Posted 26th July 2019 by Jane Williams
This article was originally published on Open Targets and is republished with kind permission.
For many cancers we don’t have an effective treatment option, and worse still, a lot of the therapies that we use are just not good enough. We need better cancer therapies, and we need them now.
The reason we need new therapies is actually the reason why I got into cancer research. It goes back to when I was only 17 when my Mam was diagnosed with acute myeloid leukemia (AML). She went through her treatment, chemotherapy, with another 12 patients, and unfortunately she was the only one who survived.
Posted 1st February 2019 by Joshua Sewell
We are lucky to be living in the middle of the digital revolution. Our access to information, products, and ability to change platforms and paradigms has never been better. Professionals shaping the digital revolution in pharmaceuticals and health care moved the leading edge further forward at the 2nd Global Pharma R&D Informatics and AI Congress.
Lab Data Automation, Optimizing R&D Workflows and Lead Discovery from Biologically Complex Bioassays
Posted 23rd January 2019 by Jane Williams
With an increasing amount of data being generated today, pharma and biotech companies need to develop new technologies and strategies in order to structure, analyse and integrate this big data. If you weren’t able to attend our Global Pharma R&D Informatics & AI Congress, we have made these slides from Ralph Haffner, Dana Caulder and Pierre Farmer available.